drugset / Trial / NCT00139698

Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

NCT00139698

Phase 3 Completed 410 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Timeline

Start
2005-09
Primary completion
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Hydrochlorothiazide Unknown 25 mg
Subject olmesartan alone or in combination with hydrochlorothiazide Unknown 20 mg
Subject olmesartan alone or in combination with hydrochlorothiazide Unknown 40 mg